4.0 Article

Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment

Related references

Note: Only part of the references are listed.
Article Ophthalmology

Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation

Julie L. Gasperini et al.

BRITISH JOURNAL OF OPHTHALMOLOGY (2012)

Article Ophthalmology

Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab

Maria Salling Eghoj et al.

BRITISH JOURNAL OF OPHTHALMOLOGY (2012)

Article Ophthalmology

TACHYPHYLAXIS AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION

Farzin Forooghian et al.

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2009)

Article Ophthalmology

SAFETY OF REPEAT INTRAVITREAL INJECTIONS OF BEVACIZUMAB VERSUS RANIBIZUMAB Our Experience After 2,000 Injections

Ioannis D. Ladas et al.

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2009)

Article Medicine, General & Internal

Ranibizumab for neovascular age-related macular degeneration

Philip J. Rosenfeld et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)

Article Medicine, General & Internal

Ranibizumab versus verteporfin for neovascular age-related macular degeneration

David M. Brown et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)